FDA Approved: IDHIFA — Supplemental Application (Celgene Corporation)

View source ↗

Summary

This FDA notice indicates that Celgene filed a supplemental application for IDHIFA (enasidenib mesylate), seeking changes to the approved label.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Acute Myeloid Leukemia

Drugs mentioned

• IDHIFA (enasidenib)

Snippet

SUPPL AP for IDHIFA (ENASIDENIB MESYLATE)